Enhanced Benzathine Analogs for Improved Inflammatory Disorder Treatment
Legal Citation
Summary of the Inventive Concept
The present inventive concept relates to enhanced benzathine analogs that exhibit improved bioavailability, reduced toxicity, and controlled release profiles, providing more effective and safer treatment options for inflammatory disorders.
Background and Problem Solved
The original patent disclosed benzathine analogs for treating inflammatory disorders, but these compounds had limitations in terms of bioavailability and toxicity. The present inventive concept addresses these limitations by introducing formulations and delivery systems that enhance the efficacy and safety of the benzathine analogs.
Detailed Description of the Inventive Concept
The new inventive concept comprises formulations of benzathine analogs with improved bioavailability, achieved through the use of excipients that enhance stability and absorption. Additionally, the inventive concept includes controlled release devices that deliver the compounds at predetermined rates and durations, ensuring sustained therapeutic effects. Furthermore, the inventive concept encompasses prophylactic methods and kits for treating inflammatory disorders, providing a comprehensive approach to disease management.
Novelty and Inventive Step
The new claims introduce novel formulations, delivery systems, and prophylactic methods that are not obvious from the original patent. The enhanced bioavailability, reduced toxicity, and controlled release profiles of the benzathine analogs represent a significant improvement over the prior art, demonstrating a non-obvious inventive step.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include different excipients, delivery systems, or dosing regimens. Variations may also include the use of different benzathine analogs or combinations thereof, as well as the incorporation of additional therapeutic agents to enhance treatment outcomes.
Potential Commercial Applications and Market
The enhanced benzathine analogs have significant commercial potential in the treatment of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, sepsis, and pneumonia. The market for these disorders is substantial, with millions of people affected worldwide, and the present inventive concept offers a valuable solution for improving treatment outcomes and reducing healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically inflammatory disorder treatment and drug delivery systems, with expertise in medicinal chemistry, pharmacokinetics, and pharmaceutical formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or pharmacological researcher with advanced degree (PhD/PharmD), experienced in drug development, formulation strategies, and understanding of inflammatory disorder treatment mechanisms
Obviousness Rationale
A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core benzathine analog technology. The disclosed improvements in bioavailability, controlled release, and formulation techniques are standard optimization strategies routinely employed by pharmaceutical researchers. These modifications would be considered routine engineering and design choices within the existing technological framework of the source patent.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,550 |
|---|---|
| Title | Benzathine analogs |
| Assignee(s) | UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, United States Government As Represented By The Department Of Veterans Affairs |